Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.
For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.
Looking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。